Search Results: 值得信賴的SPLK-1003 新版題庫上線和資格考試中的領先供應商和考試認證Splunk Splunk Enterprise Certified Admin 👄 到▛ www.newdumpspdf.com ▟搜索➽ SPLK-1003 🢪輕鬆取得免費下載最新SPLK-1003題庫
Partnering With The Best Technology and Services Providers Contract Research Organizations Alimentiv URL: https://www.alimentiv.com Phone: (604) 676 5900 Alimentiv is a GI-focused Contract Research Organization (CRO) that provides a broad range of clinical research services to pharmaceutical and biotechnology companies, and academic investigators. Alimentiv offers end-to-end services and trial management for full-service clinical trial studies…
Read More
March 24, 2021 @ 11:00 am – 3:00 pm EDT The National Academies’ Forum on Drug Discovery, Development, and Translation will host a virtual public workshop on Mar 24, 2021 as part of a web series forum of events to discuss critical policy for advancement of biopharmaceutical innovation nationally and globally. This virtual public workshop…
Read More
Excerpt from the Press Release: EXTON, Pa.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced today that its discovery engine has isolated potent antibodies capable of neutralizing several SARS-CoV-2 variants, including the South African Variant (B.1.351), in pseudovirus testing. This…
Read More
– Rebastinib in Combination with Paclitaxel Demonstrated Progression Free Survival of 9.1 months in Heavily Pretreated Patients with Platinum-Resistant Ovarian Cancer (PROC) – – Pivotal Phase 3 Study of Rebastinib plus Paclitaxel in PROC Planned to Initiate in 2022 Subject to Regulatory Feedback – – Updated Results for Vimseltinib Showed Objective Response Rate of 47%…
Read More
Meet with Christopher Kata, Director of Sales & Marketing on April 30th & May 1st 2019 at the 6th Annual Clinical Operations in Oncology Trials! Christopher Kata, Director of Sales & Marketing905 [email protected] When: April 30th & May 1st 2019 at 7:45 am – 5:00 pm Where: Burlingame, California Registration: http://www.arena-international.com/oncologywestcoast 6th Annual Clinical Operations in Oncology Trials…
Read More
Meet with Christopher Kata, during the Clinical Trials Supply East Coast Meeting in King of Prussia!
Meet with Christopher Kata, Director of Sales & Marketing on October 16th to 17th during the Clinical Trials Supply East Coast Meeting in King of Prussia, PA. Christopher Kata, Director of Sales & Marketing905 [email protected] Clinical Trials Supply East Coast When: October 16th – 17thWhere: Valley Forge Casino Resort Hotel, King of Prussia, PARegister: https://www.arena-international.com/ctseastcoast/register…
Read More
Meet with Christopher Kata, Director of Sales & Marketing on November 5yj and 6th during the DIA Annual Canadian Meeting. Christopher Kata, Director of Sales & Marketing905 [email protected] DIA Annual Canadian Meeting When: November 5th and 6thWhere: Hilton Lac-Leamy, 3 Boulevard du Casino Gatineau, QC.Register: https://www.diaglobal.org/en/conference-listing/meetings/2019/11/dia-annual-canadian-meeting Christopher Kata is attending DIA’s Annual Canadian meeting in…
Read More
Meet with Christopher Kata, Director of Sales & Marketing on September 26th at the MaRS Startup Open House in Toronto, Ontario, Canada. Christopher Kata, Director of Sales & Marketing905 [email protected] MaRS Startup Open House When: September 26th 4:00 pm -7:00 pmWhere: MaRS Building – Toronto, Ontario CanadaRegister: https://www.eventbrite.ca/e/mars-startup-open-house-tickets-69880164453 Christopher Kata is attending the MaRS Startup…
Read More
Meet with Christopher Kata, Director of Sales & Marketing on February 12th & 13th 2019 at Outsourcing in Clinical Trials West Coast ! Christopher Kata, Director of Sales & Marketing 905 999-1957 [email protected] When: February 12th & 13th 2019 at 7:30 am – 5:40 pm Where: Hyatt Regency San Francisco Airport Hotel, 1333 Bayshore Highway, Burlingame,…
Read More
First Phase 2 combination trial results presented in oral session at 2021 ASH Annual Meeting Olutasidenib with azacitidine well tolerated with a safety profile largely consistent with olutasidenib alone Molecular characteristics of olutasidenib monotherapy response reported in ASH poster presentation Excerpt from the Press Release: WATERTOWN, Mass.–(BUSINESS WIRE)–Dec. 16, 2021– Forma Therapeutics Holdings, Inc.…
Read More